P Raskin, M Rendell, MC Riddle, JF Dole, MI … - Diabetes Care, 2001 - Am Diabetes Assoc RESULTS—RSG 4 and 8 mg daily significantly improved glycemic control, which
was unchanged on PBO. By intent-to-treat analysis, treatment with RSG 8 mg plus
insulin resulted in a mean reduction from baseline in HbA 1c of 1.2% (P < ... Cited by 242 - Related articles - BL Direct - All 7 versions
J Rosenstock, D Einhorn, K Hershon, NB … - International journal of clinical practice(Esher), 2002 - cat.inist.fr The glycaemic and lipid effects of treatment with pioglitazone in combination
with a stable insulin regimen were evaluated in patients with type 2 diabetes.
Patients(n= 566) receiving stable insulin regimens for ≥ 30 days yet who ... Cited by 112 - Related articles - All 4 versions
- ►endojournals.org HE Lebovitz, JF Dole, R Patwardhan, EB … - Journal of Clinical Endocrinology & Metabolism, 2001 - Endocrine Soc This study evaluated the efficacy and safety of rosiglitazone monotherapy in
patients with type 2 diabetes. After a 4-week placebo run-in period, 493
patients with type 2 diabetes were randomized to receive rosiglitazone [2 ... Cited by 415 - Related articles - BL Direct - All 5 versions
MS Kipnes, A Krosnick, MS Rendell, JW Egan … - The American journal of medicine, 2001 - Elsevier RESULTS: Patients receiving pioglitazone + sulfonylurea had significant (P
<0.05) decreases from baseline in HbA 1C and fasting plasma glucose levels
compared with patients treated with placebo + sulfonylurea. As compared ... Cited by 235 - Related articles - BL Direct - All 8 versions
- ►zhaoys.com [PDF] V Fonseca, J Rosenstock, R Patwardhan, A … - Jama, 2000 - Am Med Assoc Context Most antidiabetic agents target only 1 of several underlying causes of
diabetes. The complementary actions of the antidiabetic agents metformin
hydrochloride and rosiglitazone maleate may maintain optimal glycemic ... Cited by 520 - Related articles - BL Direct - All 8 versions
- ►diabetesjournals.org LS Phillips, G Grunberger, E Miller, R … - Diabetes Care, 2001 - Am Diabetes Assoc From the Division of Endocrinology (LSP), Emory University School of Medicine,
Atlanta, Georgia; the Center for Molecular Medicine and Genetics and the
Department of Internal Medicine (GG), Wayne State University, Detroit, ... Cited by 204 - Related articles - BL Direct - All 6 versions
BHR Wolffenbuttel, R Gomis, S Squatrito, NP … - Diabetic Medicine, 2000 - ingentaconnect.com Methods For the intention-to-treat analysis, 574 patients (59% male, mean age 61
years) were available, randomized to receive 26 weeks of twice-daily placebo (n
= 192), rosiglitazone 1 mg (n = 199) or rosiglitazone 2 mg (n = 183) in ... Cited by 247 - Related articles - BL Direct - All 5 versions
- ►diabetesjournals.org M St John Sutton, M Rendell, P Dandona, JF … - Diabetes Care, 2002 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—Of the 203 patients randomly assigned to RSG (4 mg
bid) or glyburide (GLB) (titrated to achieve optimal glycemic control for the
first 8 weeks only to limit the risk of hypoglycemia; mean 10.5 mg/day), ... Cited by 219 - Related articles - BL Direct - All 5 versions
JJ Nolan, NP Jones, R Patwardhan, LF … - Diabetic Medicine, 2000 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 128 - Related articles - BL Direct - All 5 versions
- ►diabetesjournals.org [PDF] S Aronoff, S Rosenblatt, S Braithwaite, JW … - Diabetes Care, 2000 - Am Diabetes Assoc Pioglitazone hydrochloride, a thiazo- lidinedione compound, is a new ther-
apeutic agent for the treatment of type 2 diabetes that reduces insulin
resistance by enhancing insulin action in skeletal muscle, liver, and ... Cited by 245 - Related articles - All 6 versions
